Theragen Bio

Global genome service provider and
AI-based biopharmaceutical company, Theragen Bio

Theragen Bio provides genome service to more than 700 domestic medical and research institutes over 40 countries abroad,
being as a global genome service provider and AI-based biopharmaceutical company specializing in the development of the fourth-generation personalized anti-cancer drugs.
Theragen Bio strives to realize precision medicine based on genomic technology, thereby providing the true hope and practical solutions for welfare and health of mankind.

SCROLL

History

      

  • 2020~
  • 2nd Leap, AI-based R&D
  • 2023
    11 more patents for predicting New antigens · 3 registered
    2023
    Awarded in the pharmaceutical and biotechnology category at the 15th Seoul Success Awards 2023.
    2023
    Received a commendation from the Director of the Korea National Institute of Health at the Korea Biobank Project Symposium.(KBP)
    2023
    First in Korea to introduce Element Biosciences' AVITI sequencer.
    2023
    Initiated regular educational programs for external researchers and students as part of social commitment.
    2023
    Split-off of Theragen Health.
    2022
    Launched Theragen Bio Healthcare Lab
    2021
    Discovered antibody drugs in rectal cancer targeted
    2020
    Acquisition of neoantigen prediction patent
    2020
    Recruited Soon-myung Paik as Chief Technology Officer
    2020
    Relocated the headquarter (Pangyo Korea Biopark)
    2020
    Established Theragen Bio after physical division
    2020
    Won for 2nd consecutive years in the Dream Challenge,
    AI New Drug Development Competition
  • 2017~2019
  • Genomic big data-based
    technology advancement
  • 2019
    Won for 2nd consecutive years in the Dream Challenge,
    AI New Drug Development Competition
    2019
    Commercialized Korea's the first
    'Customized genomic analysis chip' for assets
    2019
    Appointed as a chairman of
    the Korea Bio Association's Genome Industry Council
    2018
    Developed DeepOmics™
    2018
    Selected as a state-run organization for
    the "Big Data-Based Health Risk Prediction Management Service" by the Ministry of Trade, Industry and Energy
    2017
    Korea's the first NGS clinical laboratory approved by
    the Ministry of Food and Drug Safety
    2017
    Established joint venture (CPM) cancer
    research center in Japan
  • 2009 ~ 2016
  • NGS-based genomic analysis service
  • 2015
    Introduced Illumina Hi-Seq4000 analyzer for the first time in Korea
    2015
    Published standard genome of eagle on Nature
    2014
    Published standard genome of minke whale on Nature
    2013
    Identified Korean gastric cancer genes for the first time in Korea
    2013
    Published standard genome of tiger on Nature
    2010
    Obtained genetic testing agencies certification
    2009
    Completed the first human genome map in Korea
    2009
    Established Theragen Etex Bio Institute

Location

Theragen Bio

4F, Korea Bio Park Bldg. C ,700, Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea

  • +82-1522-2382
  • +82-31-288-1293

Theargen Bio Healthcare Lab.

10F, Samhwan HIPEX Bldg. A, 240, Pangyoyeok-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea

  • +82-1522-2375
  • +82-31-288-1294

Avison Biomedical Research Center

50-1, Yonsei-ro, Seodaemun-gu, Seoul

Close